ABO blood types as a risk factor for severe symptoms of COVID-19 infection
Open Access
- 12 January 2026
- journal article
- Published by Medical University of Lublin in Current Issues in Pharmacy and Medical Sciences
- Vol. 38 (4) , 213
Abstract
Numerous studies have investigated whether the ABO blood group system influences susceptibility to SARS-CoV-2 infection and disease severity. The association between blood type and COVID-19 is thought to involve both genetic and environmental factors. The present study aimed to evaluate the relationship between ABO blood phenotypes and the severity of COVID-19 among Arab populations, with a particular focus on Iraqi patients. To assess the association between ABO blood phenotypes and the occurrence and severity of SARS-CoV-2 infection. A total of 731 patients with COVID-19 confirmed by a positive PCR test were included in the study. A control group consisted of healthy volunteers with negative PCR results and no clinical symptoms of COVID-19. In all participants, ABO blood phenotype was determined. In infected patients, disease severity and mortality were evaluated and analyzed in relation to blood group phenotype. Patients with blood group A demonstrated a higher risk of COVID-19 infection compared with non-A blood groups. In contrast, individuals with blood group O showed a significantly lower incidence of COVID-19 infection and reduced disease severity (odds ratio [OR] = 0.686; 95% confidence interval [CI]: 0.521-0.902). No statistically significant differences were observed for other blood groups. Among critically ill patients, blood group A was associated with a significantly higher mortality rate compared with non-A blood groups (OR = 3.341; 95% CI: 1.416-8.158). Blood group A is associated with an increased risk of severe COVID-19 manifestations, including pneumonia and mortality, whereas blood group O appears to confer a protective effect against severe disease.Keywords
This publication has 28 references indexed in Scilit:
- A raising dawn of pentoxifylline in management of inflammatory disorders in Covid-19Inflammopharmacology, 2022
- Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modalityInternational Immunopharmacology, 2022
- The direct and indirect effects of bioactive compounds against coronavirusFood Frontiers, 2021
- ABO blood groups, COVID-19 infection and mortalityBlood Cells, Molecules, and Diseases, 2021
- The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysisBlood Reviews, 2021
- The potential use of ABO blood group system for risk stratification of COVID-19Medical Hypotheses, 2020
- An Early Warning Score to predict ICU admission in COVID-19 positive patientsJournal of Infection, 2020
- In silico studies on the comparative characterization of the interactions of SARS‐CoV‐2 spike glycoprotein with ACE‐2 receptor homologs and human TLRsJournal of Medical Virology, 2020
- Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID‐19) implicate special control measuresJournal of Medical Virology, 2020
- ABO Blood Group and Susceptibility to Severe Acute Respiratory SyndromeJAMA, 2005